A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices (FLARE-ACS)
Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Christodoulos E. Papadopoulos, PhD
- Phone Number: +30 2313312343
- Email: chrpapado@gmail.com
Study Contact Backup
- Name: Georgios Zormpas, MD
- Phone Number: +30 2313312343
- Email: sparky.zorb@gmail.com
Study Locations
-
-
-
Thessaloniki, Greece, 54642
- Recruiting
- Ippokratio General Hospital
-
Contact:
- Georgios Zormpas, MD
- Phone Number: +30 2313312343
- Email: sparky.zorb@gmail.com
-
Principal Investigator:
- Christodoulos E. Papadopoulos, PhD
-
Principal Investigator:
- Georgios Zormpas, MD
-
Sub-Investigator:
- Georgios Kassimis, PhD
-
Sub-Investigator:
- Michael Doumas, PhD
-
Sub-Investigator:
- Aristi Boulmpou, MSc
-
Sub-Investigator:
- Nikolaos Fragakis, PhD
-
Sub-Investigator:
- Vassilios Vassilikos, PhD
-
Sub-Investigator:
- Theodoros Karapantsios, PhD
-
Sub-Investigator:
- Sotiris Evgenidis, PhD
-
Sub-Investigator:
- Konstantinos Zacharias, PhD
-
Sub-Investigator:
- Nikoleta Chatzipapa, MSc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)
- Capability of providing written informed consent
- Patients able to comply with the follow-up schedule of the study
Exclusion Criteria:
- Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction
- Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome
- Patients with congenital heart disease
- Age > 85 years
- Patients with end stage chronic kidney disease
- Patients with active malignancy or autoimmune diseases which limit their survival
- Patients with expected survival < 1 year due to other reasons
- Suboptimal echocardiographic windows
- Inability to provide written consent
- Inability to comply with the follow-up schedule of the study
- Pregnancy
- Use of intravenous drugs
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observation group
Patients hospitalized due to acute coronary syndromes (STEMI, NSTEMI)
|
Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brachial artery endothelial function assessment using the Cor-IS method compared to FMD
Time Frame: 12 months
|
The primary outcome of the study is the assessment of brachial artery endothelial function in the therapeutic approach using the Cor-IS method compared to the reference method FMD.
The indices of the FMD method (FMD%, shear rate, and FMD/shear) will be compared with the R index of the Cor-IS method at the study's baseline and during follow-up.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FMD% index and MACE
Time Frame: 12 months
|
Correlation of the FMD% index with the 3-point MACE (cardiovascular death, non-fatal acute myocardial infarction, stroke)
|
12 months
|
|
R-index and MACE
Time Frame: 12 months
|
Correlation of the R-index with the 3-point MACE (cardiovascular death, non-fatal acute myocardial infarction, stroke).
|
12 months
|
|
FMD% index and rehospitalizations for angina
Time Frame: 12 months
|
Correlation of the FMD% index with the total rehospitalizations for angina.
|
12 months
|
|
R-index and rehospitalizations for angina
Time Frame: 12 months
|
Correlation of the R-index with the total rehospitalizations for angina.
|
12 months
|
|
FMD% index and need for revascularization
Time Frame: 12 months
|
Correlation of the FMD% index and need for revascularization within 1 year from study enrollment.
|
12 months
|
|
R-index and need for revascularization
Time Frame: 12 months
|
Correlation of the R-index and need for revascularization within 1 year from study enrollment.
|
12 months
|
|
FMD% index and heart failure
Time Frame: 12 months
|
Correlation of the FMD% index and the development of heart failure within 1 year from study enrollment.
|
12 months
|
|
R-index and heart failure
Time Frame: 12 months
|
Correlation of the R-index and the development of heart failure within 1 year from study enrollment.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christodoulos E. Papadopoulos, PhD, Aristotle University of Thessaloniki, Greece
- Principal Investigator: Georgios Zormpas, MD, Aristotle University of Thessaloniki, Greece
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 198/31.5.2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.